Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.
The collaboration, launched in 2019, has successfully combined MD Anderson’s innovative clinical research infrastructure and the patient-driven drug development capabilities of the Therapeutics Discovery division with Boehringer Ingelheim’s pipeline of innovative cancer medicines and expertise in advancing breakthrough therapies. Under the new agreement, joint research will continue for five additional years.
“Our collaboration with MD Anderson strengthens our determination to find solutions for the most difficult-to-treat cancers, and this latest commitment marks an important step forward, especially in our holistic KRAS program,” said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim. “We are delighted to extend our collaboration with MD Anderson. With our shared dedication to patients and like-minded approach to innovation, we have the potential to bring the medicines to lung and gastrointestinal cancer patients that they so much need.”
The flexible nature of the VRDC agreement allows the teams to expand their lung cancer indication programs targeting KRAS and TRAILR2, including Boehringer Ingelheim’s first-in-class SOS1::pan-KRAS inhibitor (BI 1701963), inhibitors of KRAS G12C (BI 1823911) and MEK (BI 3011441), as well as a novel undisclosed bi-specific TRAILR2 agonist.
The collaboration already has resulted in a number of joint publications, conference presentations (including at the 2021 AACR Annual Meeting) and clinical trial activities. Boehringer Ingelheim is pursuing a comprehensive mutant KRAS-directed effort with multiple programs expected to enter the VRDC with MD Anderson.
“We are proud to expand our work with Boehringer Ingelheim in a very exciting drug-development space – advancing novel targeted therapies against KRAS and TRAILR2,” said Timothy Heffernan, Ph.D., Head of Oncology Research in Therapeutics Discovery at MD Anderson. “Our collaboration is built upon a strong working relationship and complementary expertise, highlighting how an academic center and a pharmaceutical company can strategically work together to advance innovative therapies for patients with cancer.”
MD Anderson’s Therapeutics Discovery division is anchored by an experienced team of drug development experts working to advance the next generation of cancer therapies. The Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) platform, led by Heffernan, performs cutting-edge translational research to rapidly advance new therapies to the patients most likely to benefit.
KRAS is the most frequently mutated cancer-causing oncogene. One in seven of all human metastatic cancers expresses KRAS mutations, with mutation rates of more than 30 percent in lung adenocarcinomas, more than 40 percent in colorectal cancers and more than 90 percent in pancreatic cancers. No approved treatments for KRAS-driven cancers exist currently, further underscoring the need for continued investment in research and development. Tumor cell-selective activation of TRAILR2 can trigger cancer cell death in indications of high medical need, including lung and gastrointestinal malignancies.
This press release is issued from our corporate headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
MD Anderson has an institutional financial conflict of interest with Boehringer Ingelheim related to this research and has therefore implemented an Institutional Conflict of Interest Management and Monitoring Plan.
Please click on the following link for ‘Notes to Editors’ and ‘References’:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Boehringer Ingelheim Corporate Center GmbH
Communications + Public Affairs
P: +49 (6132) 77-183874
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
Clayton Boldt, Ph.D.
The University of Texas MD Anderson Cancer Center
P: +1 713-792-9518
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UPL Announces Collaboration With Meiji for Exclusive Access to Flupyrimin Rice in Southeast Asia11.5.2021 06:54:00 CEST | Press release
UPL Ltd., a global provider of sustainable agriculture solutions, today announced that its subsidiary has entered into a license agreement with Japanese company, Meiji Seika Pharma Co., Ltd. for exclusive access to Flupyrimin for rice in Southeast Asia. Under the license agreement, UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia, expanding the on-going collaboration between the two companies with this compound. In addition to this latest arrangement, in 2018 UPL’s subsidiary and Meiji entered into an exclusive licensing agreement for UPL to commercialize formulations of Flupyrimin for applications in rice in India. Furthermore, in 2020, the two companies signed a long-term global commercial exclusive agreement, excluding Japan, South Korea and Taiwan and non-exclusive in China, to use Flupyrimin in seed treatment and in-furrow applications. Flupyrimin, discovered by Meiji, is a patented
IFF Reports First Quarter 2021 Results10.5.2021 22:19:00 CEST | Press release
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the first quarter ended March 31, 2021. Management Commentary “We delivered solid first quarter financials, achieving top and bottom-line growth, against a strong year-ago comparison in our first quarter as a combined company,” said IFF Chairman and CEO Andreas Fibig. “Our results are indicative of strong execution by our global team and our best-in-class portfolio of industry-leading solutions. We are also encouraged by the progress we’ve made towards our integration efforts as we are on track to deliver our previously communicated objectives.” IFF Executive Vice President and CFO, Rustom Jilla commented, “We are pleased with how we've started the year with the first quarter’s sales, operating expenses, profitability and debt leverage all ending better than we had expected. At the core of our performance was strong cost discipline and a focus on cash generation, which enabled us to make faster progress
Rimini Street Announces Fiscal First Quarter 2021 Financial Results10.5.2021 22:05:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced results for the first quarter ended March 31, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005029/en/ Rimini Street Announces Fiscal First Quarter 2021 Financial Results (Graphic: Business Wire) “For the first quarter, we remain on track to achieve our strategic growth plan to achieve $1 billion in annual revenue by 2026. We achieved record revenue of $87.9 million, up 12.6% year over year, a record active client count of 2,550, up 22.8% year over year, ended the quarter with strong billings growth of 24.2% and delivered a gross margin greater than 61%,” stated Seth A. Ravin, Rimini Street co-founder, CEO and chairman of the board. “We also continued making investments to take advantage of growi
SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic10.5.2021 22:00:00 CEST | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded up to US $1.8 million from CARB-X, a global non-profit partnership dedicated to supporting research and development to address the rising threat of drug-resistant bacteria. SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones. Funds will be used to develop a rapid test for the combined detection of Chlamydia trachomatis and Neisseria gonorrhoeae, while identifying antimicrobial resistance (AMR) of gonorrhea infections towards common antibiotic treatments. Chlamydia (CT) and gonorrhea (NG) are globally significant sexually transmitted infections with serious health complications if left untreated,1 and AMR NG is an urgent public health threat.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510
SentinelOne Named a Leader in the 2021 Gartner Magic Quadrant for Endpoint Protection Platforms10.5.2021 18:12:00 CEST | Press release
SentinelOne, the autonomous cybersecurity platform company, today announced it has been positioned by Gartner as a Leader in the 2021 Magic Quadrant for Endpoint Protection Platforms1. SentinelOne believes the placement is a testament to the company’s innovative Singularity XDR platform and scaled go-to-market execution in record time. We believe this accomplishment signifies unrivaled product-market fit, innovation, and superb customer experience across a diverse set of customer profiles. “Modern society is digital, and every place where data resides is vulnerable. Human-powered products simply cannot keep up with the exponentially growing threat landscape. Our AI-powered technology is the automated solution to modern day cyberattacks,” said Tomer Weingarten, CEO and Co-founder, SentinelOne. “We believe being named a Leader in the Gartner Magic Quadrant validates our approach and aligns with the market traction we’re experiencing. I am proud our team continues to deliver innovation, s
ESI Group Launches a “No Meeting Day” to Protect Its Employees Work-life Balance and Restore the Importance of Taking Time10.5.2021 18:00:00 CEST | Press release
ESI Group (Paris:ESI): An unbalanced equation A year ago, in the wake of COVID-19, companies began adapting to ensure the continuity of their activities during lockdown. With people bound to their homes, the opportunity to create social connections, in a professional or personal context, has strongly been affected. Indeed, as a major component of the life of many citizens, offices and workplaces are and remain a main outlet for socialization. In order to counterbalance this change, companies have utilized tools, like digital meetings, to continue connecting employees to maintain team spirit and a sense of belonging. Companies became one of the last remaining social links things when everything else was put on hold. As a result, teams’ agendas have filled up; meetings now punctuate the day, causing stress, taking away the time needed to perform various tasks and reducing focus time, pushing the workday into the evening or even the weekend. Time to breathe and take a step back: “No meeti
Schlumberger and NOV Announce Collaboration to Accelerate Adoption of Automated Drilling Solutions10.5.2021 16:00:00 CEST | Press release
Schlumberger and NOV announced today a collaboration to accelerate automated drilling solutions adoption by oil and gas operators and drilling contractors. The agreement will enable customers to combine Schlumberger surface and downhole drilling automation solutions with NOV’s rig automation platform to deliver superior well construction performance. This integrated offering enables the automation of manual workflows, improving safety, decision making, consistency, and efficiency in drilling operations. “We are pleased to collaborate with NOV and to integrate their rig automation interface with our drilling automation solutions to unlock higher performance for operators and drilling contractors. Leveraging downhole and surface automation applications, we can deliver enhancements in operations safety and efficiency, and deliver top-quartile wells for our customers consistently,” comments Olivier Le Peuch, CEO, Schlumberger. “This partnership will help accelerate customers’ adoption of d